Please provide your email address to receive an email when new articles are posted on . NEW ORLEANS — Treatment of severe tricuspid regurgitation with transcatheter repair was safe, reduced severity ...

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication for ...

Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report has been added to the Credence Research Inc.

Please provide your email address to receive an email when new articles are posted on . A transcatheter mitral valve replacement system was approved for patients at high surgical risk. The system is ...

Overview The global Transcatheter Mitral Valve Replacement (TMVR) market is witnessing rapid expansion and is expected to grow at a strong CAGR of nearly 20% during the forecast period. The increasing ...

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

Polares Medical has secured $50m through a Series C financing round to further support the development of its novel cardiac transcatheter implant, MRace, for patients with mitral regurgitation (MR).

Edwards Lifesciences EW has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 ...

SAN FRANCISCO, CA—Transcatheter mitral valve-in-valve procedures, especially those done via transseptal access, are associated with low mortality and adverse event rates as well as quality-of-life ...

The first human transcatheter aortic valve implantation (TAVI) in 2002, and several subsequent single-center series, showed the feasibility of this new approach for the treatment of patients with ...